Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · neutralLow impact
Esc

Moderna Stock Falls 6% After Citi Downgrade to Sell

Bloomberg2 min read5 sources

Why is Moderna stock down today?

Moderna (MRNA) stock fell about 6% to roughly $191 on Wednesday after Citi's downgrade to Sell, as the bank said a 222% rally since August assumes unrealistic cancer-vaccine sales.

Key numbers

Moderna share move-6%to $191.36 from $203.46 close
Citi price target$80raised from $60; ~61% below last close
Rally since August222%since Phase 3 melanoma data
Sales needed for ~$200 share price$26Byearly cancer sales; Moderna's share ~$13B
Gain in 2026~520–600%outlets disagree on exact figure
Market value~$80Bnear Regeneron's despite lower expected revenue

What happened

Moderna (MRNA) stock fell about 6% to roughly $191 on Wednesday after Citi's downgrade to Sell, as the bank said a 222% rally since August assumes unrealistic cancer-vaccine sales. Analyst Geoff Meacham cut the rating from Neutral to Sell and set a price target (his estimate of fair value) of $80, about 61% below Tuesday's close. The shares had surged after Moderna and Merck said in August that their personalized cancer vaccine, intismeran, reduced melanoma (skin cancer) relapses. Citi says a $200 share price needs about $26 billion in yearly cancer-drug sales, with $13 billion going to Moderna, nearly seven times its forecast.

Why it matters

Moderna's rally shows how quickly hopes for a new medicine can push a share price far ahead of actual sales. Citi's call is a reminder that detailed trial numbers have not yet been released. The price now assumes the vaccine works across many cancers, not just melanoma. Anyone who owns Moderna, directly or through funds, can expect big swings as those details arrive.

Who this affects

Marketneutral
Low impact
Wider market steady; the drop stayed mostly within Moderna.
Companybearish
Medium impact
Shareholders give back part of a huge 2026 gain.
Competitorsneutral
Low impact
Partner Merck and peer Pfizer held flat; little spillover.
Industrymixed
Low impact
Cancer-vaccine hopes remain, but valuations face tougher scrutiny.

Moderna vs Merck, Pfizer

ModernaMRNA$191.36-6%
MerckMRK$149.11+0.3%
PfizerPFE$28.65-0.2%

As of 2026-09-30

How we got here

  1. Merck and Moderna report intismeran plus Keytruda met main goal in Phase 3 melanoma trial.

  2. Moderna closes at $203.46, the level Citi's downside estimate is measured from.

  3. Citi cuts Moderna to Sell, raises target to $80 from $60; shares fall about 6%.

What to watch

  • Detailed intismeran trial data due at the European Society for Medical Oncology meeting.Late October 2026
  • Whether the vaccine shows benefit in other tumor types, which Citi says the price assumes.Not yet scheduled

Educational content only. Not investment advice.

More briefsAll briefs →